NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/05/2026
Voltar para busca
Dado oficial do USPTO
LIZTOX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
25
Atualização mais recente
08/05/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
23/12/2019
Data de registro
22/09/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
22/09/2020
Última transação
08/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
98
Localização do titular
KR
Examinador
VAGHANI, MAYUR C
Unidade examinadora
O30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Huons Bio Pharma Co., Ltd.
Huons Global Co., Ltd.
Representantes
Jae Youn Kim Novick, Kim & Lee, PLLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Food for babies; lactose for pharmaceutical purposes; nutritional supplements; pharmaceutical agents affecting sensory organs; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting peripheral nervous system; pharmaceutical products for the treatment of viral diseases; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals being medicines for alleviating constipation; pharmaceutical products for the treatment of bone diseases; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; pharmaceutical preparationsophthalmic preparations; pharmaceutical preparations for treating allergies; pharmaceutical products for the treatment of cancer; pharmaceutical agents for epidermis; pharmaceuticals being medicines for the treatment of gastrointestinal diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for treating asthma; pharmaceuticals being medicines for dental purposes; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for respiratory organs; pharmaceuticals being antihistamines; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for use in urology; pharmaceutical preparations for the treatment of diseases of the genitourinary system; pharmaceutical preparations for the prevention of diseases of the genitourinary system; pharmaceutical preparations for treating obesity; pharmaceuticals being cardiotonics; cardiovascular pharmaceuticals; pharmaceutical preparationsantipyretic preparations; pharmaceutical preparationsanalgesic preparations; pharmaceutical preparationsanti-inflammatory preparations; pharmaceuticals being anaesthetics; pharmaceutical products for the treatment of infectious diseases; pharmaceuticals being chemotherapeutics; pharmaceuticals being psychotropics; pharmaceutical products for skin care for animals; pharmaceutical preparations for the treatment of worms in pets; Veterinary preparationsanti-infective products for veterinary use; Veterinary preparationsveterinary vaccines; veterinary preparations for treatment of intestinal bacteria; food supplements; dietary supplements; nutraceuticals for use as dietary supplements; nutraceutical preparations for therapeutic or medical purposes for the treatment of obesity; nutraceutical preparations for therapeutic or medical purposes for the treatment of intestinal disorders; nutraceutical preparations for therapeutic or medical purposes for the treatment of allergies; nutraceutical preparations for therapeutic or medical purposes for the treatment of gastrointestinal diseases; medicated plasters; deodorantsother than for human beings or for animalsair deodorantsdeodorants for clothingdeodorants for textileshousehold deodorantsroom deodorants; bacterial preparations for medical and veterinary use; medicine casesportablefilledwith pharmaceutical preparations for the treatment of viral diseases; medicine casesportablefilledwith pharmaceutical preparations for the treatment of intestinal disorders; medicine casesportablefilledwith pharmaceutical preparations for the treatment of inflammatory diseases; sanitary pads; adhesives for dentures; diapers for incontinence; babies' diapers; diapers for pets; fly glue; mothproofing paper
Publicações
Histórico de despachos e eventos da marca no USPTO.
25 publicações encontradas
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
22/09/2025
CHLD
CHANGE OF OWNER RECEIVED FROM IB
28/08/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
30/01/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
08/01/2021
FIMP
FINAL DISPOSITION PROCESSED
08/01/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
22/12/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
22/09/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/07/2020
PUBO
PUBLISHED FOR OPPOSITION
07/07/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/06/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/06/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/05/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/05/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/05/2020
RFNT
REFUSAL PROCESSED BY IB
01/05/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/04/2020
RFRR
REFUSAL PROCESSED BY MPU
09/04/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
25/03/2020
CNRT
NON-FINAL ACTION WRITTEN
24/03/2020
DOCK
ASSIGNED TO EXAMINER
19/03/2020
MAFR
APPLICATION FILING RECEIPT MAILED
15/02/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/02/2020
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
10/02/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/02/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LIZTOX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.